Efficacy of adoptive T-cell therapy isimproved by treatment with the antioxidant N-acetyl cysteine, which limits activation-induced T-cell death

Cancer Research

Volumn 76, Issue 20, 2016, Pages 6006-6016

  Scheffel, Matthew J ^a   Scurti, Gina ^b   Simms, Patricia ^b   Garrett Mayer, Elizabeth ^a   Mehrotra, Shikhar ^a   Nishimura, Michael I ^b   Voelkel Johnson, Christina ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ATM PROTEIN; DNA; HISTONE H2AX; PROTEIN P53; SERINE; T LYMPHOCYTE RECEPTOR; ANTIOXIDANT; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL EXPANSION; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; METASTATIC MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR GROWTH; UPREGULATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CELL CULTURE; CELL NUCLEUS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASMS, EXPERIMENTAL; PHOSPHORYLATION; PHYSIOLOGY;

ACETYLCYSTEINE; ANIMALS; ANTIOXIDANTS; CELL NUCLEUS; CELLS, CULTURED; DNA DAMAGE; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MICE; NEOPLASMS, EXPERIMENTAL; PHOSPHORYLATION; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84991783841     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-0587     Document Type: Article

References (55)

1. Rosenberg S. Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med 2012;4:127ps8.
2. Siegel R, Desantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62:220-41.
3. Riddell S, Greenberg P. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods 1990;128:189-201.
4. Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, Zhou J, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 2004;173:7125-30.
5. Snow AL, Pandiyan P, Zheng L, Krummey SM, Lenardo MJ. The power and the promise of restimulation-induced cell death in human immune diseases. Immunol Rev 2010;236:68-82.
6. Hernandez-Chacon JA, Li Y, Wu RC, Bernatchez C, Wang Y, Weber JS, et al. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother 2011;34:236-50.
7. Tran KQ, Zhou J, Durflinger KH, Langhan MM, Shelton TE, Wunderlich JR, et al. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother 2008;31:742-51.
8. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+T cells. J Clin Invest 2005;115:1616-26.
9. Hombach AA, Abken H. Young T cells age during a redirected anti-tumor attack: chimeric antigen receptor-provided dual costimulation is half the battle. Front Immunol 2013;4:5-8.
10. Norell H, Zhang Y, McCracken J, Martins da Palma T, Lesher A, Liu Y, et al. CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting. Cancer Immunol Immunother 2010;59:851-62.
11. Chhabra A, Mukherji B. Death receptor-independent activation-induced cell death in human melanoma antigen-specific MHC class I-restricted TCR-engineered CD4 T cells. J Immunol 2013;191:3471-7.
12. Murray-Zmijewski F, Slee E, Lu X. A complex barcode underlies the heterogeneous response of p53 to stress. Nat Rev Mol Cell Biol 2008;9:702-12.
13. Kruse J-P, Gu W. Modes of p53 regulation. Cell 2009;137:609-22.
14. Shaulsky G, Goldfinger N, Tosky MS, Levine AJ, Rotter V. Nuclear localization is essential for the activity of p53 protein. Oncogene 1991;6:2055-65.
15. Cheng Q, Chen J. Mechanism of p53 stabilization by ATM after DNA damage. Cell Cycle 2010;9:472-8.
16. Paull TT. Mechanisms of ATM activation. Annu Rev Brioche 2015;84: 711-38.
17. Blasina A, Price BD, Turenne GA, Mcgowan CH. Caffeine inhibits the checkpoint kinase ATM. Curr Biol 1999;9:1135-8.
18. Hickson I, Zhao Y, Richardson C. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 2004;64:9152-9.
19. Banin S, Moyal L, Shieh S-Y, Taya Y, Anderson CW, Chessa L, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998;281:1674-7.
20. Norell H, Martins da Palma T, Lesher A, Kaur N, Mehrotra M, Naga OS, et al. Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-1(27-35)-reactive T cells from activation-induced cell death. Cancer Res 2009;69:6282-9.
21. Branzei D, Foiani M. Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol 2008;9:297-308.
22. Nishimura MI, Avichezer D, Custer MC, Lee CS, Chen C, Parkhurst MR, et al. MHC Class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte. Cancer Res 1999;59: 6230-8.
23. Devadas S, Zaritskaya L, Rhee SG, Oberley L, Williams MS. Discrete generation of superoxide and hydrogen peroxide by T cell receptor stimulation: selective regulation ofmitogen-activated protein kinase activation and fas ligand expression. J Exp Med 2002;195:59-70.
24. Kesarwani P, Al-Khami AA, Scurti G, Thyagarajan K, Kaur N, Husain S, et al. Promoting thiol expression increases the durability of antitumor T-cell functions. Cancer Res 2014;74:6036-47.
25. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, De Jong LA, Vyth-Dreese FA, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003;198:569-80.
26. Banerjee A, Thyagarajan K, Chatterjee S, Chakraborty P, Kesarwani P, Soloshchenko M, et al. Lack of p53 augments anti-tumor functions in cytolytic T cells. Cancer Res. 2016 Jul 27. [Epub ahead of print].
27. Zhang Y, Xiong Y. A p53 amino-terminal nuclear export signal inhibited by DNA damage-induced phosphorylation. Science 2001;292:1910-5.
28. Efeyan A, Serrano M. p53: Guardian of the genome and policeman of the oncogenes. Cell Cycle 2007;6:1006-10.
29. Dudgeon C, Chan C, Kang W, Sun Y, Emerson R, Robins H, et al. The evolution of thymic lymphomas in p53 knockout mice. Genes Dev 2014;28:2613-20.
30. Watanabe M, Moon KD, Vacchio MS, Hathcock KS, Hodes RJ. Downmodulation of tumor suppressor p53 by T cell receptor signaling is critical for antigen-specific CD4+ T cell responses. Immunity 2014;40: 681-91.
31. Park JS, Lim MA, Cho ML, Ryu JG, Moon YM, Jhun JY, et al. p53 controls autoimmune arthritis via STAT-mediated regulation of the Th17 cell/Treg cell balance in mice. Arthritis Rheum 2013;65:949-59.
32. Boldizsar F, Kis-Toth K, Tarjanyi O, Olasz K, Hegyi A, Mikecz K, et al. Impaired activation-induced cell death promotes spontaneous arthritis in antigen (cartilage proteoglycan)-specific T cell receptor-transgenic mice. Arthritis Rheum 2010;62:2984-94.
33. Yamanishi Y, Boyle DL, Pinkoski MJ, Mahboubi A, Lin T, Han Z, et al. Regulation of joint destruction and inflammation by p53 in collageninduced arthritis. Am J Pathol 2002;160:123-30.
34. Han Z, Boyle DL, Shi Y, Green DR, Firestein GS. Dominant-negative p53 mutations in rheumatoid arthritis. Arthritis Rheum 1999;42:1088-92.
35. Maas K, Westfall M, Pietenpol J, Olsen NJ, Aune T. Reduced p53 in peripheral bloodmononuclear cells from patients with rheumatoid arthritis is associated with loss of radiation-induced apoptosis. Arthritis Rheum 2005;52:1047-57.
36. Salmon M, Scheel-Toellner D, Huissoon AP, Pilling D, Shamsadeen N, Hyde H, et al. Inhibition of T cell apoptosis in the rheumatoid synovium. J Clin Invest 1997;99:439-46.
37. Okuda Y, Okuda M, Bernard CC. Regulatory role of p53 in experimental autoimmune encephalomyelitis. J Neuroimmunol 2003;135:29-37.
38. Moreno M, Negrotto L, Río J, Moubarak R, Martín I, Bustamante MF, et al. Activation-induced cell death in T lymphocytes from multiple sclerosis patients. J Neuroimmunol 2014;272:51-5.
39. Sturm A, Leite AZA, Danese S, Krivacic KA, West GA, Mohr S, et al. Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T cells in Crohn's disease and ulcerative colitis. Gut 2004;53:1624-31.
40. Van Den Brande JMH, Peppelenbosch MP, Van Deventer SJH. Treating Crohn's disease by inducing T lymphocyte apoptosis. Ann N Y Acad Sci 2002;973:166-80.
41. Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 1998;281:1677-9.
42. Porcedda P, Turinetto V, Lantelme E, Fontanella E, Chrzanowska K, Ragona R, et al. Impaired elimination of DNA double-strand break-containing lymphocytes in ataxia telangiectasia and Nijmegen breakage syndrome. DNA Repair 2006;5:904-13.
43. Sena LA, Li S, Jairaman A, Prakriya M, Ezponda T, Hildeman DA, et al. Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. Immunity 2013;38:225-36.
44. Marnett LJ. Oxyradicals and DNA damage. Carcinogenesis 2000;21:361-70.
45. Mayer PJ, Lange CS, Bradley MO, Nichols WW. Age-dependent decline in rejoining of X-ray-induced DNA double-strand breaks in normal human lymphocytes. Mutat Res 1989;219:95-100.
46. Barnett YA, Barnett CR. DNA damage and mutation: contributors to the age-related alterations in T cell-mediated immune responses?Mech Ageing Dev 1998;102:165-75.
47. Hyland P, Barnett C, Pawelec G, Barnett Y. Age-related accumulation of oxidative DNA damage and alterations in levels of in human CD4+ T cell clones in vitro. Mech Ageing Dev 2001;122:1151-67.
48. Neri S, Pawelec G, Facchini A, Mariani E. Microsatellite instability and compromised mismatch repair gene expression during in vitro passaging of monoclonal human T lymphocytes. Rejuvenation Res 2007;10: 145-56.
49. Hao LY, Strong MA, Greider CW. Phosphorylation of H2AX at short telomeres in T cells and fibroblasts. J Biol Chem 2004;279:45148-54.
50. Drissi R, Wu J, Hu Y, Bockhold C, Dome JS. Telomere shortening alters the kinetics of the DNA damage response after ionizing radiation in human cells. Cancer Prev Res 2011;4:1973-81.
51. Shen X, Zhou J, Hathcock KS, Robbins P, Powell DJ, Rosenberg SA, et al. Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J Immunother 2007;30:123-9.
52. Lenton KJ, Therriault H, Fülöp T, Payette H, Wagner JR. Glutathione and ascorbate are negatively correlated with oxidative DNA damage in human lymphocytes. Carcinogenesis 1999;20:607-13.
53. Kalamasz D, Long S, Taniguchi R, Buckner JH, Berenson RJ, Bonyhadi M. Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and anti-CD28 antibodies. J Immunother 2004;27:405-18.
54. Eylar E, Rivera-Quinones C, Molina C, Báez I, Molina F, Mercado CM. Nacetylcysteine enhances T cell functions and T cell growth in culture. Int Immunol 1993;5:97-101.
55. Mantovani G, Macciò A, Melis G, Mura L, Massa E, Mudu M. Restoration of functional defects in peripheral blood mononuclear cells isolated from cancer patients by thiol antioxidants alpha-lipoic acid and N-acetyl cysteine. Int J Cancer 2000;86:842-7.